Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Oric Pharmaceuticals Inc - news published 175 - readings 1.881

BACK

Oric Pharmaceuticals Inc

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Oric Pharmaceuticals Inc published this content on March 31, 2025 , and is solely responsible for the information contained herein. Distributed via , unedited and unaltered, on March 31, 2025 at 20:55 UTC .

31.03.2025

Oric Pharmaceuticals Inc

Initial Registration Statement for Employee Benefit Plan (Form S-8)

As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORIC PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 47-1787157 (State or other jurisdiction of incorp ...

20.03.2025

Oric Pharmaceuticals Inc

Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective March 11, 2025, the Compensation Committee of the Board of Directors (the "Committee") of ORIC Pharmaceuticals, Inc. (the "Company") approved the ORIC Pharmaceuticals, Inc. Amended and Resta ...

14.03.2025

Oric Pharmaceuticals Inc

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSIO ...

04.03.2025

Oric Pharmaceuticals Inc

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones (Form 8-K)

ORIC ® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase 3 trial in mCRPC expe ...

25.02.2025

Oric Pharmaceuticals Inc

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates (Form 8-K)

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ...

18.02.2025

Oric Pharmaceuticals Inc

Annual Report for Fiscal Year Ending 12-31, 2024 (Form 10-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: ...

18.02.2025

Oric Pharmaceuticals Inc

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Oric Pharmaceuticals Inc published this content on February 18, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 18, 2025 at 21:36:31.037 .

18.02.2025

Oric Pharmaceuticals Inc

Regulation FD Presentation Form 8 K

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Oric Pharmaceuticals Inc published this content on January 13, 2025 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 13, 2025 at 13:32:27.425 .

13.01.2025

Oric Pharmaceuticals Inc

ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC 114 in Combination with Amivantamab for the First Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Oric Pharmaceuticals Inc published this content on January 13, 2025 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 13, 2025 at 13:26:30.048 .

13.01.2025

Oric Pharmaceuticals Inc

Statement of Changes in Beneficial Ownership (Form 4)

Ownership Submission FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES A ...

06.01.2025

Oric Pharmaceuticals Inc

Statement of Changes in Beneficial Ownership (Form 4)

06.01.2025

Oric Pharmaceuticals Inc

Statement of Changes in Beneficial Ownership (Form 4)

06.01.2025

Oric Pharmaceuticals Inc

Statement of Changes in Beneficial Ownership (Form 4)

06.01.2025

Oric Pharmaceuticals Inc

Statement of Changes in Beneficial Ownership (Form 4)

06.01.2025

Oric Pharmaceuticals Inc - news published 175 - readings 1.881

Oric Pharmaceuticals Inc

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Oric Pharmaceuticals Inc

Initial Registration Statement for Employee Benefit Plan (Form S-8)

Oric Pharmaceuticals Inc

Management Change/Compensation (Form 8-K)

Oric Pharmaceuticals Inc

Statement of Changes in Beneficial Ownership (Form 4)

Oric Pharmaceuticals Inc

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones (Form 8-K)

Oric Pharmaceuticals Inc

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates (Form 8-K)

Oric Pharmaceuticals Inc

Annual Report for Fiscal Year Ending 12-31, 2024 (Form 10-K)

Oric Pharmaceuticals Inc

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

Oric Pharmaceuticals Inc

Regulation FD Presentation Form 8 K

Oric Pharmaceuticals Inc

ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC 114 in Combination with Amivantamab for the First Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

Oric Pharmaceuticals Inc

Statement of Changes in Beneficial Ownership (Form 4)

Oric Pharmaceuticals Inc

Statement of Changes in Beneficial Ownership (Form 4)

Oric Pharmaceuticals Inc

Statement of Changes in Beneficial Ownership (Form 4)

Oric Pharmaceuticals Inc

Statement of Changes in Beneficial Ownership (Form 4)

Oric Pharmaceuticals Inc

Statement of Changes in Beneficial Ownership (Form 4)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member